Elu­ci­da On­col­o­gy nabs more funds for its take on AD­Cs, sees po­ten­tial in ra­dio­ther­a­py part­ner­ship

Elu­ci­da On­col­o­gy has raised an­oth­er ap­prox­i­mate­ly $30 mil­lion to bring its ver­sion of an­ti­body-drug con­ju­gates to more pa­tients in the clin­i­cal set­ting, the com­pa­ny told …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER